Joshua Hare, M.D., believes that anything is possible. For
the past five years he has led groundbreaking research at
The Johns Hopkins University, helping dispel a long-standing
theory: that doctors cannot repair a damaged heart. Now he
brings that research and much of his team to the Miller School
of Medicine, where he has been named professor of medicine
and biomedical engineering, chief of the Division of Cardiology,
and director of the new Interdisciplinary Stem Cell Institute.
Most believe he will help elevate the school’s reputation
and work in cardiology to a world-class level.
Hare’s pioneering work involves the
use of stem cell therapy to repair damage to hearts, a relatively
During the past five years Hare has led the heart failure
program at Johns Hopkins.
This new field of research has advanced rapidly
in a short time. Just three years ago cardiologists believed
to the heart was permanent. That is quickly changing as the
field moves forward. Hare expects much more progress in the
coming years through his work at the Miller School.
“We’re going to bring a major research program
using bench-to-bedside research,” he says. “We
are seeking to develop novel therapies and take them rapidly
from laboratories into the clinic.”
His work is widely published, including recent
articles in The Journal of the American Medical Association,
England Journal of Medicine, Nature, Circulation, and Circulation
Research. But Hare devotes much of his energy applying the
findings to help patients.
“A lot of scientists work in labs and make discoveries,
then others have to pick it up and move it into clinics,” he
says. “But we are different. Through translational
research, we do it soup to nuts. We’re the guys who
will develop the therapy, work in laboratories, and do the
Thus far, much of his work has involved patients
who need heart transplants. He believes that rapidly developing
will soon provide much better options and a real sense of
hope for those patients and their families.
“Repairing damaged hearts has always
been one of the holy grails of cardiology,” he says. “The
idea that you can repair injuries is a very exciting concept
in my field. It’s really the ultimate goal of medicine.
“Translational research is a very exciting and promising
emphasis for a program to have,” Hare adds. “It
recognizes that scientific discoveries should be taken into
But first we have to get past some perceived stumbling blocks,
including the dichotomy of what the government is willing
to pay for in research and what people really want that will
impact on public health.”
Hare brings a number of ongoing clinical trials
and a host of researchers with him to the University. He
says at least
eight of his colleagues are moving to Miami to join him in
continuing work they began at Hopkins. Together they plan
to advance this rapidly developing field. Soon the group
will enjoy new state-of-the-art facilities in the Inter-disciplinary
Wet Laboratory in the Biomedical Research Institute, which
is currently under construction on campus.
His landmark work has long impressed Pascal
J. Goldschmidt, M.D., senior vice president for medical affairs
of the Miller School of Medicine. It was Goldschmidt who
recently convinced Hare to bring his work to Miami. Goldschmidt
says he was especially impressed with Hare’s passion
for advancing medicine.
“He rejects the idea that we are doing enough for our
patients with injured hearts,” says Goldschmidt. “The
need is for novel interventions that aim at reconstituting
normal cardiac tissue where the heart has been destroyed.
This opportunity is unmatched, barely explored, and incredibly
As for his moving to Miami, Hare says he and
his colleagues are very excited about many things, including
difference in weather between South Florida and Maryland.
“I think Miami is a terrific city, and this institution
is a great place,” he says. “I’m deeply
impressed with my colleagues already at the Miller School
a very close and long-standing relationship with the dean.
That was certainly a huge part of it. But I’m also
very impressed by the institution at every step of the way.
I just feel like this is the right thing at the right time.”
And Hare can’t wait to get started.
“I believe we’re going to be a leader in this
rapidly advancing field of cardiovascular regeneration,” he
says. “We’re going to be the leading center in